a novel antibody targeting cd24 and hepatocellular carcinoma in vivo by near-infrared fluorescence imaging：一种新型抗体靶向cd24和肝细胞癌的实验研究利用近红外荧光成像.pdf

Immunobiology 220 (2015) 1328–1336 Contents lists available at ScienceDirect Immunobiology j o u r n a l h o m ep a g e: w w w. elsev /locate/imbi o A novel antibody targeting CD24 and hepatocellular carcinoma in vivo by near-infrared fluorescence imaging Hua He 1, Xiaojie Tu 1, Juan Zhang ∗ , Desmond Omane Acheampong, Li Ding, Zhaoxiong Ma, Xueyan Ren, Chen Luo, Zhiguo Chen, Tong Wang, Wei Xie, Min Wang ∗ State Key Laboratory of Natural Medicines (China Pharmaceutical University), School of Life Science Technology, China Pharmaceutical University, Nanjing 210009, PR China a r t i c l e i n f o a b s t r a c t Article history: Liver cancer is one of the most common malignant cancers worldwide. The poor response of liver cancer Received 5 January 2015 to chemotherapy has whipped up the interest in targeted therapy with monoclonal antibodies because Received in revised form 13 March 2015 of its potential efficiency. One promising target is cluster of differentiation 24 (CD24), which is known Accepted 7 July 2015 to beover-expressed on hepatocellular carcinoma (HCC), providing prospect for HCC targeted diagnosis Available online 26 July 2015 and therapy. In this study we developed a novel CD24 targeted monoclonal antibody G7mAb based on hybridoma technology and then generated a single-chain antibodyfragment (scFv) G7S. Firstly, ELISA, Keywords: western blot, and flow cytom